| Literature DB >> 31398481 |
Amber C Streifel1, Monica K Sikka2, Christina D Bowen3, James S Lewis4.
Abstract
Dalbavancin is a lipoglycopeptide antibiotic with unique weekly dosing active against Gram-positive organisms. This retrospective study included 37 patients receiving a mean of 2.7 weeks of dalbavancin. Nine patients (24%) were re-admitted to the hospital within 30 days. A total of 617 hospital days were saved, estimated to result in US$1 495 336 in savings and a mean cost avoidance of US$40 414 per patient. Dalbavancin provides a valuable antibiotic option that may minimise healthcare expenditure.Entities:
Keywords: Dalbavancin; Gram-positive infection; OPAT; Outpatient parenteral antimicrobial therapy
Mesh：
Substances：
Year: 2019 PMID： 31398481 DOI： 10.1016/j.ijantimicag.2019.08.007
Source DB: PubMed Journal: Int J Antimicrob Agents ISSN： 0924-8579 Impact factor: 5.283